Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CAPR

Capricor Therapeutics Inc

Nov 28 • 02:39PM ET

2.93

Dollar change -0.06
Percentage change -2.01	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.15	Insider Own	8.81%	Shs Outstand	30.79M	Perf Week	-1.35%
Market Cap	90.21M	Forward P/E	-	EPS next Y	-1.10	Insider Trans	0.85%	Shs Float	28.08M	Perf Month	7.72%
Income	-29.25M	PEG	-	EPS next Q	-0.07	Inst Own	17.99%	Short Float / Ratio	4.86% / 5.35	Perf Quarter	-51.93%
Sales	14.05M	P/S	6.42	EPS this Y	9.60%	Inst Trans	8.01%	Short Interest	1.36M	Perf Half Y	-33.41%
Book/sh	-0.07	P/B	-	EPS next Y	-2.81%	ROA	-64.22%	Target Price	22.33	Perf Year	-28.01%
Cash/sh	0.93	P/C	3.16	EPS next 5Y	-	ROE	-428.87%	52W Range	2.68 - 8.22	Perf YTD	-24.09%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-893.77%	52W High	-64.36%	Beta	3.95
Dividend %	-	Quick Ratio	0.90	Sales past 5Y	154.89%	Gross Margin	93.36%	52W Low	9.33%	ATR	0.16
Employees	74	Current Ratio	0.90	Sales Q/Q	288.66%	Oper. Margin	-219.67%	RSI (14)	43.18	Volatility	3.63% 4.84%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	5.10%	Profit Margin	-208.16%	Rel Volume	0.20	Prev Close	2.99
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 14 AMC	Payout	-	Avg Volume	255.03K	Price	2.93
Recom	1.00	SMA20	0.59%	SMA50	-13.74%	SMA200	-34.59%	Volume	40,358	Change	-2.01%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-26-22	Initiated	Ladenburg Thalmann	Buy	$15
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy	$6.50 → $8.60
Sep-15-17	Reiterated	H.C. Wainwright	Buy	$2.15 → $6.50
Feb-13-17	Resumed	Rodman & Renshaw	Buy	$14
Jul-06-16	Resumed	H.C. Wainwright	Buy	$13
Jun-15-16	Initiated	ROTH Capital	Buy

Nov-16-23 08:28AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:30PM	Capricor: Q3 Earnings Snapshot (Associated Press Finance) +5.99%
04:05PM	Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 09:15AM	Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14 (GlobeNewswire)
Nov-02-23 10:00AM	Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline (Zacks)
09:35AM	Loading…
Oct-25-23 09:35AM	After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR) (Zacks)
Oct-24-23 09:35AM	After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR) (Zacks)
Oct-19-23 04:01PM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program (GlobeNewswire)
Oct-10-23 09:00AM	Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-29-23 07:35AM	Capricor Therapeutics Announces $23 Million Registered Direct Offering (GlobeNewswire) -41.19%
07:30AM	Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-06-23 09:00AM	Capricor Therapeutics Appoints Michael Kelliher to Board of Directors (GlobeNewswire)
Aug-08-23 01:44PM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2023 Earnings Call Transcript (Insider Monkey) +21.66%
Aug-07-23 04:51PM	Capricor: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
04:01PM	Loading…
Aug-02-23 04:01PM	Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7 (GlobeNewswire)
Jul-24-23 08:30AM	Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors (GlobeNewswire)
Jul-13-23 08:30AM	Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors (GlobeNewswire)
Jul-06-23 12:27PM	The past five years for Capricor Therapeutics (NASDAQ:CAPR) investors has not been profitable (Simply Wall St.)
Jun-30-23 09:25AM	Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-13-23 09:15AM	Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-09-23 11:28AM	We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate (Simply Wall St.)
Jun-07-23 09:15AM	Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
May-13-23 09:18AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares Could Be 27% Above Their Intrinsic Value Estimate (Simply Wall St.)
May-11-23 04:22PM	Capricor: Q1 Earnings Snapshot (AP Finance)
04:01PM	Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-23 09:00AM	Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11 (GlobeNewswire)
Apr-27-23 09:00AM	Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX Platform (GlobeNewswire)
Mar-23-23 09:25AM	Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-20-23 11:27AM	When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable? (Simply Wall St.)
03:12AM	Loading…
Mar-18-23 03:12AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-15-23 04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-08-23 09:00AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15 (GlobeNewswire)
Mar-02-23 09:15AM	Capricor Therapeutics Receives Clinical Research Forums 2023 Top Ten Clinical Research Achievement Award (GlobeNewswire)
Feb-16-23 09:25AM	Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan (GlobeNewswire) +10.42%
Jan-25-23 08:00AM	Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients (GlobeNewswire)
Jan-19-23 04:05PM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program (GlobeNewswire)
Jan-12-23 12:55PM	Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study (Benzinga)
09:26AM	Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform (GlobeNewswire)
Jan-11-23 12:00PM	Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Dec-10-22 07:46AM	Despite shrinking by US$18m in the past week, Capricor Therapeutics (NASDAQ:CAPR) shareholders are still up 194% over 3 years (Simply Wall St.)
Nov-30-22 10:35AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $15 (TipRanks) +11.19%
Nov-13-22 07:18AM	Capricor Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 05:15PM	Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Edited Transcript of CAPR.OQ earnings conference call or presentation 10-Nov-22 9:30pm GMT (Thomson Reuters StreetEvents)
04:01PM	Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-22 04:01PM	Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10 (GlobeNewswire)
Oct-06-22 09:00AM	Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022 (GlobeNewswire)
Sep-07-22 08:00AM	Capricor Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.57%
Aug-10-22 04:05PM	Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-22 08:00AM	Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10 (GlobeNewswire)
Jul-19-22 09:15AM	Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) +5.25%
Jun-27-22 07:00AM	Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study (GlobeNewswire)
Jun-17-22 09:00AM	Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference (GlobeNewswire) +7.83%
May-25-22 09:00AM	Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer (GlobeNewswire)
May-18-22 09:00AM	Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-10-22 04:01PM	Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 08:30AM	Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10 (GlobeNewswire)
May-02-22 10:08AM	Loss-Making Capricor Therapeutics, Inc. (NASDAQ:CAPR) Expected To Breakeven In The Medium-Term (Simply Wall St.) +9.78%
Mar-29-22 09:00AM	Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit (GlobeNewswire) -11.43%
Mar-28-22 12:06PM	Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial (Benzinga) -32.22%
08:30AM	Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients (GlobeNewswire)
Mar-11-22 08:00AM	The Lancet Publishes Positive Results from Capricor Therapeutics Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-10-22 04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -9.45%
Mar-03-22 09:15AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10 (GlobeNewswire)
Mar-02-22 09:00AM	Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development (GlobeNewswire)
Feb-15-22 06:27AM	We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate (Simply Wall St.) +8.54%
Jan-25-22 02:58PM	Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US (PR Newswire) +21.55%
11:06AM	Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy Candidate (Benzinga)
05:00AM	Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S. (GlobeNewswire)
Dec-30-21 07:57AM	Forget Bargains, Play 5 Stocks With Rising P/E Instead (Zacks)
Dec-13-21 09:15AM	Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19 (GlobeNewswire)
Nov-19-21 10:00AM	Here's Why Capricor (CAPR) is Poised for a Turnaround After Losing 19.3% in 4 Weeks (Zacks)
Nov-17-21 05:24AM	When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit? (Simply Wall St.)
Nov-12-21 09:15AM	Capricors CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day (GlobeNewswire)
Nov-09-21 06:45PM	Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-21 07:30AM	SHAREHOLDER ALERT: Morris Kandinov Investigating FFIE, CAPR, COO, and SEMOX; Shareholders are Encouraged to Contact the Firm (GlobeNewswire)
Nov-02-21 04:05PM	Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9 (GlobeNewswire)
Sep-24-21 09:28AM	Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71% (Benzinga)
07:00AM	Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002 (GlobeNewswire)
Sep-22-21 04:05PM	Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences (GlobeNewswire)
Sep-07-21 09:00AM	Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-02-21 08:30AM	Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021 (GlobeNewswire) +5.63%
Aug-19-21 09:45AM	We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-12-21 04:01PM	Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-21 09:00AM	Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12 (GlobeNewswire)
Jul-27-21 08:00AM	Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors (GlobeNewswire)
Jun-23-21 08:27AM	Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength? (Zacks) -8.74%
Jun-17-21 09:00AM	Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference (GlobeNewswire) +15.00%
Jun-13-21 02:37PM	Hedge Funds Are Betting On Capricor Therapeutics, Inc. (CAPR) (Insider Monkey)
Jun-10-21 09:15AM	Capricor Therapeutics to Participate in BIO Digital 2021 Conference (GlobeNewswire)
May-18-21 08:30AM	Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting (GlobeNewswire)
May-13-21 04:05PM	Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -6.78%
02:30PM	Capricor Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
May-12-21 09:00AM	Capricor to Present at the American Society of Gene and Cell Therapys 24th Annual Meeting (GlobeNewswire)
May-06-21 08:30AM	Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13 (GlobeNewswire) -7.84%
Apr-29-21 08:00AM	Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio (GlobeNewswire) +14.94%
Mar-13-21 01:28AM	Breakeven On The Horizon For Capricor Therapeutics, Inc. (NASDAQ:CAPR) (Simply Wall St.)
Mar-11-21 04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update (GlobeNewswire)

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Oct 23	Option Exercise	1.39	2,178	3,027	2,381	Oct 24 09:25 AM
Musket David B	Director	Oct 12	Buy	2.75	410	1,128	31,536	Oct 13 01:59 PM
COLLIER EARL M JR	Director	Oct 10	Buy	2.83	10,000	28,300	26,856	Oct 12 09:15 AM
Musket David B	Director	Oct 09	Buy	2.82	5,083	14,334	31,126	Oct 11 09:15 AM
Auwaerter Paul Gisbert	Director	Oct 06	Buy	2.84	5,000	14,200	5,000	Oct 10 09:15 AM
Musket David B	Director	Oct 04	Buy	2.90	2,500	7,250	26,043	Oct 06 09:15 AM
Litvack Frank	Director	Aug 14	Option Exercise	1.39	20,748	28,840	137,633	Aug 16 05:00 PM
Marban Linda	CHIEF EXECUTIVE OFFICER	May 12	Option Exercise	1.39	20,749	28,841	198,604	May 16 07:00 PM
Avat Xavier	Former CBO	Apr 17	Sale	4.35	14,772	64,258	0	Apr 27 05:28 PM
Avat Xavier	FORMER CHIEF BUSINESS OFFICER	Apr 05	Option Exercise	3.46	84,791	293,377	84,791	Apr 07 05:00 PM
Avat Xavier	FORMER CHIEF BUSINESS OFFICER	Mar 28	Sale	4.06	3,000	12,180	0	Apr 07 05:00 PM
Litvack Frank	Director	Feb 21	Option Exercise	1.39	14,027	19,498	141,800	Feb 23 09:00 AM
Manzo Louis	Director	Feb 21	Option Exercise	1.39	1,401	1,947	62,599	Feb 23 09:00 AM
COLLIER EARL M JR	Director	Feb 14	Option Exercise	1.39	1,401	1,947	16,856	Feb 15 08:00 PM
DUNBAR GEORGE W JR	Director	Feb 14	Option Exercise	1.39	1,401	1,947	10,556	Feb 15 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAPR

Capricor Therapeutics Inc

Upgrade your FINVIZ experience